Is artesunate safe for use during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Is Artesunate Safe in Pregnancy?

Artesunate is safe and effective for treating malaria during the second and third trimesters of pregnancy, and should be considered during the first trimester when other treatment options are unavailable or when treating severe malaria in any trimester. 1

Treatment Recommendations by Trimester

Second and Third Trimesters

Artemisinin-based combination therapies (ACTs), including artesunate-containing regimens, are recommended as safe treatment options at standard adult doses. 1 The CDC's 2018 guidelines specifically endorse artemether-lumefantrine (which contains artemether, closely related to artesunate) based on:

  • Multiple clinical trials comparing ACTs with quinine-based regimens showing no differences in pregnancy outcomes (miscarriage, stillbirth, congenital malformations) 1
  • Meta-analyses demonstrating no association between ACT treatment and adverse pregnancy outcomes 1
  • Fewer maternal adverse events (particularly tinnitus, dizziness, vomiting) compared to quinine-based regimens 1

First Trimester

The evidence is more nuanced but reassuring:

  • Preferred options remain mefloquine or quinine plus clindamycin 1
  • However, artemisinin-based therapies should be considered when preferred options are unavailable 1

The safety data from first trimester exposure includes:

  • A large pooled analysis of 717 women exposed to artemisinin regimens showed no increased risk of miscarriage compared to quinine (adjusted HR 0.73,95% CI 0.44-1.21) or no treatment 1
  • Studies from the Thai-Myanmar border found no increased miscarriage risk with artesunate treatment 2
  • Multiple observational studies detected no increased risk of congenital anomalies 1, 3

Severe Malaria: All Trimesters

For severe malaria, intravenous artesunate is the preferred treatment in all trimesters, including the first. 4 This recommendation is based on:

  • Superior efficacy compared to quinine in randomized trials 4
  • No detected increase in miscarriage, stillbirth, or congenital anomalies with first trimester exposure 4
  • The life-threatening nature of severe malaria outweighs theoretical concerns 4

Key Safety Evidence

Pregnancy Outcomes

Research from multiple settings demonstrates:

  • No increase in congenital malformations 5, 3
  • Similar rates of miscarriage and stillbirth compared to other antimalarials 1, 2
  • No increase in perinatal, neonatal, or infant mortality 5
  • Potentially improved birth weights when malaria is effectively cleared 6

Important Context

The evidence shows that untreated malaria itself poses significant risks:

  • Asymptomatic malaria increases miscarriage risk 2.7-fold 2
  • Symptomatic malaria increases miscarriage risk 4-fold 2
  • Higher parasitemia and severe malaria further increase miscarriage risk 2

Clinical Algorithm

For uncomplicated malaria:

  • Second/Third trimester: Use artemisinin-based combinations at standard doses
  • First trimester: Prefer mefloquine or quinine-clindamycin; use artemisinin-based therapy if these are unavailable

For severe malaria:

  • Any trimester: Use intravenous artesunate immediately—this is life-saving treatment

Common Pitfalls to Avoid

  1. Don't delay treatment in first trimester due to theoretical concerns—untreated malaria carries documented substantial risks to both mother and fetus 2

  2. Don't use quinine when artesunate is available for severe malaria—artesunate has superior efficacy and safety profile 4

  3. Don't assume all artemisinin derivatives have identical safety profiles—most data specifically addresses artemether-lumefantrine and artesunate, though class effects appear consistent 1

Strength of Evidence

The 2018 CDC guidelines 1 represent the most authoritative and recent guidance, based on systematic review of 16 studies for second/third trimester safety and multiple observational studies for first trimester exposure. The WHO has endorsed these recommendations and is considering expanding first-trimester indications based on accumulating safety data 1. The evidence base includes randomized trials, large cohort studies, and meta-analyses consistently showing safety across pregnancy trimesters 5, 4, 2.

References

3
Research

Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women.

Annals of tropical medicine and parasitology, 2009

6
Research

The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy.

Transactions of the Royal Society of Tropical Medicine and Hygiene, 2001

Related Questions

What is the recommended empirical intravenous artesunate regimen for pregnant women with suspected or confirmed severe malaria?
What should be done if a double dose of intravenous artesunate is administered by mistake?
Does artesunate cause clinically significant QT‑interval prolongation?
Can artesunate be given empirically to a pregnant woman with high‑grade fever when malaria is suspected?
What is the recommended artesunate dosing regimen for severe malaria, including intravenous administration and transition to oral therapy?
Is the PIK3CA H1047R mutation more commonly associated with intestinal cancers than ovarian cancers in a 54‑year‑old woman with unresectable adnexal and omental masses and a small appendiceal adenocarcinoma?
What should be evaluated before starting neoadjuvant chemotherapy in a patient with pancreatic head adenocarcinoma?
What nasal continuous positive airway pressure (CPAP) settings should be used for a newborn with pneumonia?
In a 62‑year‑old male with type 2 diabetes, past alcohol use (now abstinent), fatty liver disease (CAP 229 dB/m, FibroScan stiffness 24 kPa), fluctuating gamma‑glutamyl transferase, stable bilirubin, normal renal function, and currently taking gliclazide, metformin, linagliptin, empagliflozin, rosiglitazone, and prescribed saroglitazar (not taken), what adjustments to his antidiabetic regimen and liver‑directed therapy are recommended?
How should mucus leakage from the anal canal and rectum be managed after a colostomy?
In a 44-year-old woman 7 days after sinus micro‑surgery and septoplasty, who is receiving cefuroxime and azithromycin, presents with fever, musculoskeletal pain, elevated C‑reactive protein, and a maculopapular rash on the upper limbs and trunk, what is the differential diagnosis and recommended next steps in management?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.